Refine Search

New Search

Results: 2

(searched for: (title:(Famotidine Research Progress)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Aamir Jalal Al Mosawi
Journal of Biomedical Research & Environmental Sciences, Volume 2, pp 021-029; doi:10.37871/jbres1181

Abstract:
There has been an increasing interest in famotidine research within the scientific medical community because of the emerging preliminary evidence suggesting its possible beneficial role in patients with COVID‑19. The aim of this paper to provide an overview of famotidine research progress relevant to COVID‑19.
Published: 23 December 2020
Frontiers in Medicine, Volume 7; doi:10.3389/fmed.2020.614393

Abstract:
Famotidine is of interest as a possible treatment for COVID-19, with effects on disease-related symptoms and survival reported in observational and retrospective studies, as well as in silico predictions of binding to potential SARS-CoV-2 drug targets. Published studies of famotidine for COVID-19 have focused on acute illness, and none have reported on neuropsychiatric symptoms. This case study reports on an 18-year-old man who sought psychiatric treatment for depression and anxiety, disruptive interpersonal conflicts, and impairments in attention and motivation following mildly symptomatic illness with COVID-19. The neuropsychiatric symptoms, which had been present for 16 weeks at the time of the initial evaluation represented a significant departure from the patient's previous behavioral baseline. The patient had no prior psychiatric history preceding his illness with COVID-19, and no history of any prior treatment with psychopharmacological medications. Famotidine 20 mg twice daily administered orally was begun without any additional medications. At 1-week follow-up the patient was much improved. Improvement was sustained through 12 weeks of follow-up during which the patient continued to take famotidine without apparent side effects. With progression of the COVID-19 pandemic it has become evident that persistent disease-related symptoms may follow acute COVID-19 and may include neuropsychiatric symptoms. Controlled clinical research on famotidine for COVID-19 should follow, as well as the development of valid and reliable research diagnostic criteria to define and operationalize the features of a putative COVID-19 neuropsychiatric residual.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top